IITRI NEWS
NEWS
We are ready to answer your questions and provide guidance.
News
Partner News: NCI Project Team Award for Inhaled COVID-19 Candidate APN-01
IITRI is happy to share the good news from our collaboration with the National Cancer Institute (NCI) on their program focusing on an inhaled drug against SARS-CoV-2. Our team here at IITRI was contracted to perform toxicology studies for their drug...
Sponsor News: Antiviral activity of Ascletis’ candidates against SARS-CoV-2
IITRI is happy to share the promising news of one of our Sponsors, Ascletis Pharma, Inc. Our team here at IITRI was contracted to perform in vitro testing of their drug candidates for antiviral effects against multiple strains of SARS-CoV-2 as well as cytotoxicity....
See You Soon at the SOT Annual Meeting in San Diego!
We're excited to be attending the 61st Annual Meeting and ToxExpo (March 27-31, 2022) in sunny San Diego after two years of delayed and virtual meetings. You can find us at the Expo at Booth #2307 from March 28-30 in the Exhibit Hall (ground level) from 9am- 4:30pm....
Service Spotlight : Vaccine Challenge and Toxicology Studies
August is National Immunization Awareness Month (NIAM) which serves as reminder of the importance of vaccination for people of all ages. We're proud to play a role in the development and testing of vaccines here at IITRI. IITRI has decades of experience conducting...
Service Spotlight: Exposure Atmosphere Characterization
STARTING OFF ON THE RIGHT FOOT Our inhalation services include preliminary method development activities as the necessary first step for inhalation toxicology studies. The selection and characterization of the test atmosphere to be realistic and extensively measured...
New Partner Publications- Promising COVID-19 Studies
IITRI is proud to share the promising news from multiple sponsors of COVID-19 in vitro and in vivo studies. Links below to press releases and recent publications. Congrats all! New IITRI Co-Author Publication: Scalable live-attenuated SARS-CoV-2 vaccine...
SARS-CoV-2 Variants of Concern Now Available
IITRI now has access to multiple SARS-CoV-2 variants. Currently available: B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma). Available soon: B.1.617.1 (Kappa) and B.1.617.2 (Delta) These variants are available for use in our assays (immunostain and neutralization) as well...
Immunostain SARS-CoV-2 Efficacy Assay Available
IITRI now offers an improved efficacy assay for looking at effects of drugs on SARS-CoV-2. Although this assay no longer includes a cytotoxicity readout, we offer a neutral red assay in BSl-2 instead if needed. This current assay uses immunostaining and provides more...
American College of Toxicology (Virtual) 41st Meeting
Even though we were saddened to hear that the 41st Annual Meeting of the American College of Toxicology (Nov 12-19) will not take place in the wonderful city of Austin this year, we support this decision and are very much looking forward to participating in the...
Hamster and ferret models available for COVID-19 studies
Ferret infection model: Since early in the pandemic, IITRI has been working on developing new animal models to test out therapeutics and treatments for COVID-19 (in addition to in vitro offerings of efficacy assays, neutralization assays, and surface decontaminant...
Recent Comments